References in periodicals archive ?
The choice of the dose of trypsin-like proteinase inhibitor for the treatment of white mice infected with IAV.
[ClickPress, Fri Aug 23 2019] This report on the tyrosine kinase inhibitors market analyzes the current and future scenario of the global market.
As an inhibitor of ULK, DCC-3116 is designed to address mutant RAS cancers by inhibiting the basal and compensatory autophagy that mutant RAS cancer cells use for their survival.
M-120 contains inhibitors that have an attraction to metal and desire to conform to the intricacies of metal surfaces, providing a protective layer in micro-cavities for fuller inhibitor coverage.
The National Institute for Health and Care Excellence (NICE) guidelines on T2DM management list both SGLT-2 inhibitors and DPP-4 inhibitors among the potential options for intensifying therapy after metformin.4 The American Association of Clinical Endocrinologists and the American College of Endocrinology guidelines do include a hierarchical recommendation to try a GLP-1 agonist first, followed by an SGLT-2 inhibitor, followed by a DPP-4 inhibitor, after metformin and lifestyle modifications--although the difference in strength of recommendations for these classes is noted to be small.
Presence of inhibitor is confirmed if aPTT value is greater than mean value in test tube three.
"HRs for all-cause death consistently favored SGLT-2 inhibitor vs.
In this section, we studied the influence of three factors: corrosion inhibitor concentration, Cl[O.sub.2] concentration, and pH value, on the corrosion inhibition efficiency of corrosion of carbon steel.
Historically, if a patient has demonstrated a prolonged PT and aPTT with a normal TT, this is thought to be pathognomonic for an FV inhibitor. (22) However, antibodies to factor X, although exceedingly rare, may produce a similar profile, and some of the newly developed oral direct factor Xa inhibitor medications will prolong the PT and aPTT but not the TT and will show an inhibitor pattern in a mixing study.
31 October 2017 - US-based oncology drug development company Xynomic Pharma has acquired exclusive global rights to develop, manufacture and commercialize BI 882370, a 2nd-generation RAF inhibitor, from German drugmaker Boehringer Ingelheim, the company said.
The reviewers found that pneumonitis was significantly linked to PD-1/PD-Ll inhibitor therapy (P less than .001) and colitis to CTLA-4 treatment (P = .04), even after accounting for therapeutic dose and tumor type.

Full browser ?